Sign in Sign up for free

Last updated: 17 June 2024 at 4:41pm EST

Karen Shoos Net Worth




The estimated Net Worth of Karen L. Shoos is at least $1.37 Million dollars as of 6 December 2013. Ms. Shoos owns over 17,728 units of Celldex Therapeutics stock worth over $1,293,380 and over the last 15 years she sold CLDX stock worth over $0. In addition, she makes $75,614 as Independent Chairman of the Board at Celldex Therapeutics.

Ms. Shoos CLDX stock SEC Form 4 insiders trading

Karen has made over 2 trades of the Celldex Therapeutics stock since 2010, according to the Form 4 filled with the SEC. Most recently she exercised 17,728 units of CLDX stock worth $144,660 on 6 December 2013.

The largest trade she's ever made was exercising 17,728 units of Celldex Therapeutics stock on 6 December 2013 worth over $144,660. On average, Karen trades about 1,091 units every 62 days since 2009. As of 6 December 2013 she still owns at least 31,061 units of Celldex Therapeutics stock.

You can see the complete history of Ms. Shoos stock trades at the bottom of the page.





Karen Shoos biography

Karen Lipton Shoos serves as Independent Chairman of the Board of the Company. Ms. Shoos is currently a consultant in international blood safety and since November 2015, Ms. Shoos has been the Director of Operations for the Maryland Tech Council Venture Mentoring Services Program. From May 2013 to September 2016, Ms. Shoos was Principal Investigator, AABB International Technical Assistance. From October 1994 to May 2013, Ms. Shoos was Chief Executive Officer of AABB. AABB is a professional standards setting and accrediting organization in the fields of blood and cellular therapies. Prior to AABB, from 1984 to 1994, Ms. Shoos held senior positions at the American Red Cross, including Acting Senior Vice

What is the salary of Karen Shoos?

As the Independent Chairman of the Board of Celldex Therapeutics, the total compensation of Karen Shoos at Celldex Therapeutics is $75,614. There are 13 executives at Celldex Therapeutics getting paid more, with Ronald Pepin having the highest compensation of $1,225,030.



How old is Karen Shoos?

Karen Shoos is 66, she's been the Independent Chairman of the Board of Celldex Therapeutics since 2019. There are 5 older and 19 younger executives at Celldex Therapeutics. The oldest executive at Celldex Therapeutics Inc. is Herbert Conrad, 87, who is the Independent Director.

What's Karen Shoos's mailing address?

Karen's mailing address filed with the SEC is C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON, NJ, 08827.

Insiders trading at Celldex Therapeutics

Over the last 16 years, insiders at Celldex Therapeutics have traded over $19,527,314 worth of Celldex Therapeutics stock and bought 273,450 units worth $1,157,166 . The most active insiders traders include Rajesh B Parekh, Garry Arthur Neil, and Inc Medarex. On average, Celldex Therapeutics executives and independent directors trade stock every 69 days with the average trade being worth of $1,750,671. The most recent stock trade was executed by Samuel Bates Martin on 14 June 2024, trading 20,169 units of CLDX stock currently worth $204,917.



What does Celldex Therapeutics do?

celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. celldex therapeutics (nasdaq: cldx) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. the company's pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers, including many underserved or completely un-served orphan indications. this has created a leading pipeline in im



What does Celldex Therapeutics's logo look like?

Celldex Therapeutics Inc. logo

Complete history of Ms. Shoos stock trades at Celldex Therapeutics

Date
#
Company
 Insider
Trans.
Transaction
 Shares Price per share Total value Shares after Source
6 Dec 2013 CLDX Celldex Therapeutics Inc. Karen L. Shoos
Option 17,728 $8.16 $144,660
6 Dec 2013
31,061 ↗
16 Sep 2010 CLDX Celldex Therapeutics Inc. Karen L. Shoos
Buy 3,000 $3.74 $11,220
16 Sep 2010
3,000 ↗


Celldex Therapeutics executives and stock owners

Celldex Therapeutics executives and other stock owners filed with the SEC include: